Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America

Figures & data

Table 1 Patients fully hospitalized at least once per period and length of stay by period (n = 78)

Patients fully hospitalized1
Period	R	P		P value*
3 months	17 (21.8)	1 (1.3)		<0.001
6 months	22 (28.2)	4 (5.1)		<0.001
Total length of stay (days)2
	R	P	P – R	P value**
3 months	7.6 0 (18.3)	0.4 0 (3.2)	−7.2 0 (17.2)	<0.001
6 months	13 0 (30)	2.1 0 (10.9)	−11 0 (30.9)	0.002

1 Notes: Values shown are the number of patients (%);

2 Values shown are the mean (median, SD);

* P value associated with the hypothesis of no difference between retrospective and prospective periods (McNemar’s test);

** P values for difference P – R calculated using paired t-test.

Abbreviations: R, retrospective; P, prospective; SD, standard deviation.

Figure 1 Evolution of PSP scores over time.

Notes: Only patients with a PSP score at both baseline and six months are included in this table. *P-value associated with the hypothesis of no difference from baseline (paired t-test). Change from baseline [mean (SD)]: All patients: baseline vs three months 15 (15.5) P < 0.001 and baseline vs six months 16.3 (17,2) P < 0.001; Outpatients: baseline vs three months 14.7 (15.1) P < 0.001 and baseline vs six months 15.9 (16.9) P < 0.001; Inpatients: baseline vs three months 18.5 (22), n.s. and baseline vs six months 20.7 (21.1), n.s.
Abbreviation: n-s, not significant.

Table 2 Antipsychotics taken, by class, with each class counted only once (n = 79)

Antipsychotic class		Retrospective period				Baseline n (%)	Prospective period
		−12 months n (%)	−9 months n (%)	−6 months n (%)	−3 months n (%)		3 months n (%)	6 months n (%)
OA:	Any	24 (30.4)	25 (31.6)	29 (36.7)	28 (35.4)	36 (45.6)	8 (10.1)	7 (8.9)
	Risperidone	12 (15.2)	13 (16.5)	12 (15.2)	14 (17.7)	29 (36.7)	4 (5.1)	4 (5.1)
	Olanzapine	6 (7.6)	6 (7.6)	7 (8.9)	6 (7.6)	2 (2.5)	0 (0)	0 (0)
OC		15 (19)	17 (21.5)	19 (24.1)	18 (22.8)	14 (17.7)	4 (5.1)	3 (3.8)
DC		9 (11.4)	10 (12.7)	9 (11.4)	10 (12.7)	2 (2.5)	0 (0)	0 (0)
RLAI		0 (0)	0 (0)	0 (0)	0 (0)	79 (100)	79 (100)	78 (98.7)

Note: Each patient can appear more than once per time point.

Abbreviations: OA, oral atypical; OC, oral conventional; DC, depot conventional; RLAI, risperidone long-acting injectable.

Figure 2 Concomitant therapy.

Notes: Each patient can have more than one medication per timepoint. *P-value associated with the hypothesis of no change from baseline to six months (McNemar test on the patients with an evaluation at both visits).